Title: Expressing support for continued investment to complete the development of an HIV vaccine.
Policy area: Health

Summary:
This resolution expresses support for the domestic development of a vaccine for HIV.

[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 1506 Introduced in House (IH)]

<DOC>






117th CONGRESS
  2d Session
H. RES. 1506

Expressing support for continued investment to complete the development 
                           of an HIV vaccine.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                            December 1, 2022

    Ms. Williams of Georgia (for herself and Ms. Lee of California) 
submitted the following resolution; which was referred to the Committee 
                         on Energy and Commerce

_______________________________________________________________________

                               RESOLUTION


 
Expressing support for continued investment to complete the development 
                           of an HIV vaccine.

Whereas HIV affects the entire globe and exists in a variety of subtypes;
Whereas, in 2019, the estimated number of new HIV infections in adults and 
        adolescents was approximately 34,800, and the overall rate of new HIV 
        infections was 12.6 cases per 100,000 people in the United States;
Whereas, at the end of 2019, the estimated HIV prevalence rate for persons 13 
        years of age and older in the United States was 431.0 per 100,000 
        people;
Whereas, as of 2019, Black Americans have a rate of HIV infection that is 8.1 
        times higher than that of White Americans;
Whereas, in 2019, there were 6.0 cases of HIV per 100,000 people that progressed 
        from HIV to AIDS in the United States;
Whereas, at the end of 2019, the AIDS prevalence rate among adults and 
        adolescents in the United States was estimated at 192.3 per 100,000 
        people;
Whereas, each year, more than 12,000 people with AIDS die in the United States;
Whereas the people diagnosed with HIV in 2018 in the United States will pay a 
        combined estimated lifetime total of $13,700,000,000 in direct medical 
        expenses;
Whereas it is estimated that patients on antiretroviral therapy with access to 
        discounted medication have lifetime medical costs averaging $420,285, 
        which rises to an average of $1,079,999 for patients without such 
        access, based on an estimated life expectancy of 37.31 years after 
        diagnosis;
Whereas, in fiscal year 2022 alone, United States Federal domestic discretionary 
        funding for HIV/AIDS programs totaled $7,425,800,000;
Whereas the United States has contributed a total of $23,170,000,000 since 2002 
        to the Global Fund to Fight AIDS, Tuberculosis and Malaria, a 
        multilateral effort supported by a number of countries and 
        nongovernmental organizations;
Whereas alternatives for preventing HIV transmission, formerly limited to 
        abstinence, education, circumcision, and condoms, now include HIV 
        prevention medicines such as preexposure prophylaxis (PrEP) and 
        postexposure prophylaxis (PEP);
Whereas 3 HIV vaccines (BG505 MD39.3 mRNA, BG505 MD39.3 gp151 mRNA, and BG505 
        MD39.3 gp151 CD4KO mRNA) are currently in National Institutes of Health-
        funded phase 1 trials;
Whereas President Biden has pledged to develop and implement a comprehensive 
        national HIV/AIDS strategy that will include a focus on reducing HIV 
        incidence; and
Whereas continued government investment toward a viable HIV vaccine has the 
        potential to improve public health in the United States: Now, therefore, 
        be it
    Resolved, That the House of Representatives strongly encourages 
domestic efforts in the public and private sectors to invest in and 
complete the development of a vaccine for HIV.
                                 <all>